| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arginine | 2 | 2021 | 102 | 1.430 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 133 | 1.340 |
Why?
|
| S-Nitrosoglutathione | 5 | 2021 | 87 | 1.140 |
Why?
|
| Nitric Oxide Synthase | 7 | 2005 | 163 | 1.070 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2018 | 48 | 0.960 |
Why?
|
| Inflammation | 6 | 2021 | 1030 | 0.860 |
Why?
|
| Peroxisomes | 2 | 2019 | 48 | 0.770 |
Why?
|
| Neuroprotective Agents | 2 | 2015 | 317 | 0.770 |
Why?
|
| Neuroglia | 5 | 2005 | 136 | 0.760 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2020 | 115 | 0.750 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 99 | 0.740 |
Why?
|
| Nitric Oxide | 6 | 2018 | 382 | 0.740 |
Why?
|
| Enzyme Inhibitors | 5 | 2021 | 659 | 0.710 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 132 | 0.700 |
Why?
|
| Lovastatin | 2 | 2018 | 78 | 0.660 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 182 | 0.660 |
Why?
|
| tau Proteins | 2 | 2015 | 61 | 0.620 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 371 | 0.610 |
Why?
|
| Lipopolysaccharides | 7 | 2005 | 455 | 0.590 |
Why?
|
| Cholestasis | 1 | 2017 | 90 | 0.580 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2018 | 105 | 0.570 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 176 | 0.560 |
Why?
|
| Endosonography | 1 | 2017 | 177 | 0.550 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 2550 | 0.540 |
Why?
|
| Animals | 27 | 2021 | 20881 | 0.530 |
Why?
|
| Signal Transduction | 5 | 2019 | 2689 | 0.520 |
Why?
|
| May-Thurner Syndrome | 1 | 2015 | 1 | 0.520 |
Why?
|
| Endothelial Cells | 1 | 2018 | 384 | 0.520 |
Why?
|
| Iliac Vein | 1 | 2015 | 10 | 0.510 |
Why?
|
| Vascular Patency | 1 | 2015 | 122 | 0.500 |
Why?
|
| Psychosine | 2 | 2013 | 33 | 0.480 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 348 | 0.480 |
Why?
|
| Leukodystrophy, Globoid Cell | 2 | 2013 | 27 | 0.480 |
Why?
|
| Venous Thrombosis | 2 | 2015 | 125 | 0.480 |
Why?
|
| Membrane Microdomains | 2 | 2010 | 32 | 0.440 |
Why?
|
| Mitochondria | 1 | 2018 | 643 | 0.430 |
Why?
|
| Rats | 13 | 2015 | 5300 | 0.420 |
Why?
|
| Oligodendroglia | 1 | 2013 | 107 | 0.410 |
Why?
|
| Cell Survival | 3 | 2015 | 901 | 0.400 |
Why?
|
| Cells, Cultured | 10 | 2018 | 2673 | 0.400 |
Why?
|
| Mice | 10 | 2021 | 8474 | 0.380 |
Why?
|
| Lactosylceramides | 2 | 2007 | 27 | 0.360 |
Why?
|
| Sphingomyelins | 1 | 2010 | 106 | 0.350 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1034 | 0.350 |
Why?
|
| Amyloid beta-Peptides | 2 | 2015 | 191 | 0.350 |
Why?
|
| Transcription Factors | 2 | 2004 | 753 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2013 | 342 | 0.340 |
Why?
|
| Brain Ischemia | 1 | 2015 | 665 | 0.340 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2021 | 32 | 0.340 |
Why?
|
| Neurons | 2 | 2015 | 881 | 0.320 |
Why?
|
| Bile Ducts | 2 | 2018 | 59 | 0.300 |
Why?
|
| Second Messenger Systems | 1 | 2007 | 53 | 0.300 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2008 | 201 | 0.290 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2003 | 18 | 0.280 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 142 | 0.270 |
Why?
|
| Pyrroles | 3 | 2021 | 83 | 0.270 |
Why?
|
| Lipoxygenase | 1 | 2005 | 13 | 0.260 |
Why?
|
| Phospholipases A | 1 | 2005 | 41 | 0.260 |
Why?
|
| Cell Line | 4 | 2018 | 1752 | 0.250 |
Why?
|
| Cyclic AMP | 2 | 2005 | 223 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 2791 | 0.250 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2004 | 39 | 0.240 |
Why?
|
| Oxidation-Reduction | 4 | 2018 | 567 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 86 | 0.240 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 134 | 0.240 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 2 | 2021 | 21 | 0.230 |
Why?
|
| Benzamides | 3 | 2021 | 156 | 0.230 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2003 | 10 | 0.230 |
Why?
|
| Female | 14 | 2021 | 38074 | 0.230 |
Why?
|
| Sphingolipids | 1 | 2006 | 337 | 0.210 |
Why?
|
| Humans | 18 | 2021 | 68618 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 226 | 0.210 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2004 | 183 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 2083 | 0.200 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2021 | 17 | 0.200 |
Why?
|
| Stents | 3 | 2018 | 657 | 0.200 |
Why?
|
| Glucose | 1 | 2003 | 307 | 0.200 |
Why?
|
| Pertussis Toxin | 1 | 2021 | 72 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2021 | 16 | 0.190 |
Why?
|
| Phosphorylation | 5 | 2015 | 1200 | 0.190 |
Why?
|
| Adenosine Triphosphate | 2 | 2018 | 314 | 0.190 |
Why?
|
| Macrophages | 1 | 2004 | 647 | 0.190 |
Why?
|
| Myeloid Cells | 1 | 2021 | 57 | 0.180 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.180 |
Why?
|
| Gene Expression | 2 | 2018 | 770 | 0.180 |
Why?
|
| Hypoxia | 1 | 2021 | 169 | 0.180 |
Why?
|
| Th17 Cells | 1 | 2021 | 116 | 0.180 |
Why?
|
| Transfection | 4 | 2013 | 782 | 0.180 |
Why?
|
| Ceramides | 1 | 2004 | 578 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 163 | 0.180 |
Why?
|
| Organelle Biogenesis | 1 | 2019 | 34 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 186 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2017 | 119 | 0.170 |
Why?
|
| Chronic Disease | 2 | 2015 | 1330 | 0.170 |
Why?
|
| Mice, Knockout | 2 | 2021 | 1692 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 1851 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 87 | 0.160 |
Why?
|
| Bile Duct Diseases | 1 | 2018 | 28 | 0.160 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2015 | 64 | 0.160 |
Why?
|
| Tyrosine | 2 | 2018 | 196 | 0.160 |
Why?
|
| Male | 12 | 2021 | 37321 | 0.160 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 334 | 0.160 |
Why?
|
| Cytokines | 3 | 2021 | 866 | 0.160 |
Why?
|
| Spinal Cord Injuries | 2 | 2021 | 551 | 0.160 |
Why?
|
| NF-kappa B | 5 | 2015 | 432 | 0.150 |
Why?
|
| Ribonucleotides | 1 | 2018 | 26 | 0.150 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2018 | 25 | 0.150 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 32 | 0.150 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2018 | 37 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2018 | 60 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 101 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2017 | 7029 | 0.150 |
Why?
|
| Calpain | 2 | 2015 | 205 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2021 | 506 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2017 | 82 | 0.150 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 1033 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2018 | 7277 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1040 | 0.140 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 16 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2018 | 244 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 199 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 209 | 0.140 |
Why?
|
| Cisplatin | 2 | 2015 | 192 | 0.130 |
Why?
|
| Maze Learning | 2 | 2015 | 138 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Middle Aged | 8 | 2018 | 21147 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 231 | 0.130 |
Why?
|
| Phlebography | 1 | 2015 | 31 | 0.130 |
Why?
|
| Synaptosomes | 1 | 2015 | 57 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2013 | 160 | 0.130 |
Why?
|
| Nitric Oxide Donors | 1 | 2015 | 54 | 0.130 |
Why?
|
| Transcriptional Activation | 3 | 2005 | 226 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2018 | 400 | 0.120 |
Why?
|
| Proline | 2 | 2005 | 52 | 0.120 |
Why?
|
| Brain | 3 | 2015 | 2176 | 0.120 |
Why?
|
| Liver | 1 | 2019 | 1118 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 282 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2017 | 413 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 73 | 0.110 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2013 | 31 | 0.110 |
Why?
|
| Galactosylceramidase | 1 | 2013 | 11 | 0.110 |
Why?
|
| Galactosylceramides | 1 | 2013 | 12 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 508 | 0.110 |
Why?
|
| Transcription Factor AP-1 | 2 | 2003 | 61 | 0.110 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2012 | 9 | 0.110 |
Why?
|
| Foot | 1 | 2013 | 66 | 0.110 |
Why?
|
| Microscopy, Electron | 1 | 2013 | 351 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 20 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2013 | 954 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2012 | 39 | 0.100 |
Why?
|
| Myelin Sheath | 1 | 2013 | 115 | 0.100 |
Why?
|
| Palliative Care | 2 | 2012 | 271 | 0.100 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.100 |
Why?
|
| Alloys | 1 | 2012 | 66 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 261 | 0.100 |
Why?
|
| RNA Interference | 1 | 2013 | 266 | 0.100 |
Why?
|
| Drainage | 1 | 2012 | 133 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 186 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2017 | 447 | 0.100 |
Why?
|
| Ischemia | 1 | 2013 | 229 | 0.100 |
Why?
|
| Random Allocation | 1 | 2013 | 442 | 0.100 |
Why?
|
| Wound Healing | 1 | 2013 | 260 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 4848 | 0.090 |
Why?
|
| Benzodioxoles | 2 | 2021 | 30 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2018 | 1615 | 0.090 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 61 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 629 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2017 | 3705 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 561 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 366 | 0.080 |
Why?
|
| Cholesterol | 1 | 2010 | 331 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 791 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 60 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2005 | 189 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 290 | 0.080 |
Why?
|
| Enzyme Induction | 2 | 2005 | 119 | 0.080 |
Why?
|
| Heptanoic Acids | 1 | 2008 | 28 | 0.080 |
Why?
|
| Leupeptins | 2 | 2005 | 23 | 0.080 |
Why?
|
| Young Adult | 2 | 2018 | 5717 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2013 | 1451 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 415 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 149 | 0.070 |
Why?
|
| Astrocytes | 3 | 2004 | 270 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2005 | 241 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 27 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 212 | 0.070 |
Why?
|
| Adult | 5 | 2018 | 21403 | 0.070 |
Why?
|
| Seizures | 1 | 2008 | 279 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 32 | 0.060 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 14 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 86 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2324 | 0.060 |
Why?
|
| Adenosine Kinase | 1 | 2005 | 6 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2005 | 191 | 0.060 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2004 | 5 | 0.060 |
Why?
|
| Colforsin | 1 | 2004 | 42 | 0.060 |
Why?
|
| Hippocampus | 1 | 2008 | 471 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 69 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 29 | 0.060 |
Why?
|
| RNA | 1 | 2005 | 171 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2004 | 74 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2005 | 305 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 308 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2003 | 6 | 0.060 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2003 | 8 | 0.060 |
Why?
|
| Response Elements | 1 | 2003 | 29 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2003 | 29 | 0.060 |
Why?
|
| NADP | 1 | 2003 | 39 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2004 | 230 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 981 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2004 | 1664 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 468 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 331 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 852 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2006 | 718 | 0.050 |
Why?
|
| Cellular Microenvironment | 1 | 2021 | 10 | 0.050 |
Why?
|
| Aldehydes | 1 | 2021 | 34 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 3259 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2019 | 31 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 329 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 114 | 0.040 |
Why?
|
| Warm Ischemia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Protein S | 1 | 2018 | 9 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 104 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2018 | 75 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1745 | 0.040 |
Why?
|
| Ethiodized Oil | 1 | 2017 | 4 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1056 | 0.040 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2017 | 8 | 0.040 |
Why?
|
| Living Donors | 1 | 2018 | 160 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 5731 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 132 | 0.030 |
Why?
|
| Thiocarbamates | 2 | 2005 | 20 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| Disease | 1 | 2014 | 41 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 626 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 649 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2013 | 39 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 172 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 2012 | 6 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1083 | 0.030 |
Why?
|
| Angioplasty | 1 | 2013 | 118 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 483 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1447 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 756 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1046 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 365 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 565 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Ectodysplasins | 1 | 2008 | 7 | 0.020 |
Why?
|
| Kainic Acid | 1 | 2008 | 44 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 88 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 329 | 0.020 |
Why?
|
| Portal Vein | 1 | 2006 | 46 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 8912 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2006 | 130 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 349 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2005 | 67 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 2004 | 7 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 47 | 0.010 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 57 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 165 | 0.010 |
Why?
|
| Morpholines | 1 | 2004 | 79 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 137 | 0.010 |
Why?
|
| Glioma | 1 | 2005 | 140 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 507 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2004 | 222 | 0.010 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2004 | 86 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 301 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 742 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 284 | 0.010 |
Why?
|
| Antioxidants | 1 | 2004 | 304 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 260 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2004 | 296 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 247 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1641 | 0.010 |
Why?
|